Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. 02315
02315 logo

02315 Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
51.950
Open
51.000
VWAP
48.30
Vol
2.05M
Mkt Cap
--
Low
45.860
Amount
98.98M
EV/EBITDA(TTM)
128.55
Total Shares
--
EV
44.52B
EV/OCF(TTM)
131.22
P/S(TTM)
35.40

Events Timeline

No data

No data

News

aastocks
4.5
2025-12-24aastocks
HSI Rises 44 Points in Half-Day Trading as SMIC Jumps Over 3% and BIOCYTOGEN-B Surges 20%
  • Market Performance: On December 24, the HSI rose by 44 points (0.17%) to close at 25,818, with a total market turnover of $92.524 billion. The HSCEI and HSTECH also saw slight increases.

  • US Tariff Extension: The US has extended the deadline for additional tariffs on Chinese chips to June 2027, impacting market dynamics.

  • Stock Movements: SMIC's share price increased by 3.1% after raising production prices, while Cathay Pacific's stock fell 0.5% due to leadership changes.

  • Notable Stock Changes: Biocytogen-B surged 22.2% after being added to the Southbound Stock Connect, while Playmates Toys dropped over 14% due to a licensing agreement expiration.

aastocks
2.0
2025-12-24aastocks
BIOCYTOGEN-B Surges Over 20% Following Inclusion in Southbound Stock Connect
  • Stock Performance: BIOCYTOGEN-B (02315.HK) surged by 22.79% to HKD35.24, with a trading volume of 9.837 million shares worth HKD327 million.

  • Market Inclusion: The Shenzhen and Shanghai Stock Exchanges announced that BIOCYTOGEN-B is now eligible for the Southbound Stock Connect, effective today (24th).

aastocks
2.0
2025-12-24aastocks
BIOCYTOGEN-B Now Included in Securities Eligible for Southbound Stock Connect, Effective Immediately
  • Stock Addition Announcement: The Shenzhen Stock Exchange has added BIOCYTOGEN-B (02315.HK) to the list of securities eligible for the Southbound Stock Connect, effective today, October 24th.

  • Stock Performance: Following the announcement, BIOCYTOGEN-B experienced a significant increase in its stock price, rising by 6.320, which represents a 22.021% gain.

Businesswire
8.5
2025-12-10Businesswire
Biocytogen Lists on STAR Market, Opening Price Surges 117% to 58 RMB
  • Listing Milestone: Biocytogen successfully lists on the STAR Market with an IPO price of 26.68 RMB, opening at 58 RMB, a 117% increase, resulting in a market cap exceeding 25.9 billion RMB, marking its position as the first “H+A” dual-listed global drug innovator.
  • Platform Advantage: The company’s RenMice® platforms enable the discovery of fully human monoclonal antibodies across over 1,000 druggable targets, having advanced more than 40 PCC-to-IND stage assets, showcasing its robust capabilities in antibody drug development.
  • Global Collaborations: Biocytogen has established over 280 global discovery partnerships and successfully out-licensed more than 10 clinical or near-clinical programs, further solidifying its leadership in the global biotechnology sector.
  • Strategic Expansion: This listing will facilitate Biocytogen's global expansion and platform commercialization, leveraging the synergies of its “H+A” dual-listing structure to deepen collaborations with international partners and drive the discovery of novel therapies to benefit global healthcare.
Businesswire
8.5
2025-12-10Businesswire
Biocytogen Lists on Shanghai STAR Market, Opens 117% Higher
  • Listing Milestone: Biocytogen successfully listed on the Shanghai STAR Market with an IPO price of 26.68 RMB per share, opening at 58 RMB, which represents a 117% increase over the offering price and a market capitalization exceeding 25.9 billion RMB, marking its status as the first “H+A” dual-listed global drug innovator.
  • Platform Advantage: The company leverages its RenMice® platforms to support the discovery of fully human monoclonal antibodies across over 1,000 druggable targets, having advanced more than 40 assets from PCC to IND stage, showcasing its leadership in antibody drug development.
  • Global Collaborations: Biocytogen has established over 280 global discovery partnerships, including more than 10 successful out-licensing clinical or near-clinical programs, further solidifying its influence in the international market.
  • Strategic Expansion: This listing will facilitate Biocytogen's global expansion and platform commercialization, leveraging the synergies of its “H+A” dual-listing structure to deepen collaborations with international partners and drive the discovery of novel therapies to benefit global healthcare.
Businesswire
9.0
2025-12-05Businesswire
Biocytogen's Partner IDEAYA Receives FDA Clearance for Phase 1 Trial of IDE034
  • Clinical Trial Approval: IDEAYA has received FDA clearance to initiate a Phase 1 clinical trial for IDE034, with patient enrollment expected to begin in Q1 2026, marking a significant milestone for Biocytogen in the development of bispecific antibody-drug conjugates (ADCs).
  • Technical Validation: IDE034, a bispecific B7H3/PTK7 TOP1 ADC independently developed by Biocytogen, will drive subsequent clinical development following its licensing, showcasing Biocytogen's technical capabilities in bispecific ADC discovery and development.
  • Anti-Tumor Activity: Preclinical studies have demonstrated that IDE034 monotherapy induces deep and durable tumor regressions in multiple B7H3/PTK7-positive tumor models, indicating its strong anti-tumor activity and potential to offer new therapeutic options for patients.
  • Combination Strategy Exploration: IDEAYA plans to explore combination strategies with its PARG inhibitor IDE161 to enhance response durability and intends to present additional preclinical data supporting the combination rationale at a major medical conference in H1 2026.
Wall Street analysts forecast 02315 stock price to rise
0 Analyst Rating
Wall Street analysts forecast 02315 stock price to rise
0 Buy
0 Hold
0 Sell
Current: 0.000
sliders
Low
Averages
High
Current: 0.000
sliders
Low
Averages
High
No data

No data

Valuation Metrics

The current forward P/E ratio for (02315.HK) is 72.21, compared to its 5-year average forward P/E of -15.24. For a more detailed relative valuation and DCF analysis to assess 's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-15.24
Current PE
72.21
Overvalued PE
8.46
Undervalued PE
-38.95

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-25.95
Current EV/EBITDA
56.15
Overvalued EV/EBITDA
70.48
Undervalued EV/EBITDA
-122.37

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
4.46
Current PS
13.65
Overvalued PS
9.69
Undervalued PS
-0.76

Financials

AI Analysis
Annual
Quarterly

Whales Holding 02315

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is (02315) stock price today?

The current price of 02315 is 46.6 USD — it has decreased -0.3

What is (02315)'s business?

What is the price predicton of 02315 Stock?

Wall Street analysts forecast 02315 stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for 02315 is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is (02315)'s revenue for the last quarter?

revenue for the last quarter amounts to NaN USD, decreased

What is (02315)'s earnings per share (EPS) for the last quarter?

. EPS for the last quarter amounts to USD, decreased

How many employees does (02315). have?

(02315) has 0 emplpoyees as of July 02 2026.

What is (02315) market cap?

Today 02315 has the market capitalization of 0.00 USD.